Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer

Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer

Androgen receptor (AR) antagonist MDV3100 is the first therapeutic approach in treating castration-resistant prostate cancer (CRPC), but tumours frequently become drug resistant via multiple mechanisms including AR amplification and mutation. Here we identify the small molecule Ailanthone (AIL) as a...

Full description

Bibliographic Details
Main Authors: He, Yundong, Peng, Shihong, Wang, Jinhua, Chen, Huang, Cong, Xiaonan, Chen, Ang, Hu, Meichun, Qin, Min, Wu, Haigang, Gao, Shuman, Wang, Liguo, Wang, Xin, Yi, Zhengfang, Liu, Mingyao
Format: Online
Language:English
Published: Nature Publishing Group 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159881/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159881/

Similar Items